[fcb5af]: / literature / by_gene / CD70.tsv

Download this file

# pmid doi year title Hugo_Symbol
1 34318583 10.1111/aos.14993 2022 Vitreous proteomics, a gateway to improved understanding and stratification of diverse uveitis aetiologies. CD70
2 34726773 10.1002/cncr.34005 2022 Cusatuzumab for treatment of CD70-positive relapsed or refractory cutaneous T-cell lymphoma. CD70
3 34872108 10.1182/bloodadvances.2021005714 2022 Targeting CD70 in cutaneous T-cell lymphoma using an antibody-drug conjugate in patient-derived xenograft models. CD70
4 35041763 10.1111/bjd.21018 2022 Mogamulizumab induces long-term immune restoration and reshapes tumour heterogeneity in Sézary syndrome. CD70
5 35266562 10.1002/ajh.26523 2022 Mantle cell lymphoma in 2022-A comprehensive update on molecular pathogenesis, risk stratification, clinical approach, and current and novel treatments. CD70
6 35317330 10.14740/wjon1436 2022 Non-GCB Diffuse Large B-Cell Lymphoma With an Atypical Disease Course: A Case Report and Clinical Exome Analysis. CD70
7 35443163 10.1016/j.celrep.2022.110713 2022 A single-cell atlas of diffuse large B cell lymphoma. CD70
8 35474464 10.1111/his.14670 2022 CD70 is a potential target biomarker in peripheral T-cell lymphomas. CD70
9 35687490 10.1182/bloodadvances.2021006654 2022 Genomic characterization of lymphomas in patients with inborn errors of immunity. CD70
10 35787399 10.1016/j.jid.2022.06.005 2022 The Robust Tumoricidal Effects of Combined BET/HDAC Inhibition in Cutaneous T-Cell Lymphoma Can Be Reproduced by ΔNp73 Depletion. CD70
11 36055572 10.1016/j.clim.2022.109105 2022 A novel immune-related epigenetic signature based on the transcriptome for predicting the prognosis and therapeutic response of patients with diffuse large B-cell lymphoma. CD70
12 33666760 10.1007/s00262-021-02895-7 2021 Boosting CAR T-cell responses in lymphoma by simultaneous targeting of CD40/4-1BB using oncolytic viral gene therapy. CD70
13 33777778 10.3389/fonc.2021.628807 2021 Mutational Profile and Clonal Evolution of Relapsed/Refractory Diffuse Large B-Cell Lymphoma. CD70
14 33827115 10.1182/blood.2020009482 2021 CD27 is required for protective lytic EBV antigen-specific CD8+ T-cell expansion. CD70
15 33996677 10.3389/fped.2021.615724 2021 Specific Immune Response and Cytokine Production in CD70 Deficiency. CD70
16 33996698 10.3389/fped.2021.662645 2021 Different Apples, Same Tree: Visualizing Current Biological and Clinical Insights into CTLA-4 Insufficiency and LRBA and DEF6 Deficiencies. CD70
17 34189576 10.1182/blood.2020010527 2021 SOX11, CD70, and Treg cells configure the tumor-immune microenvironment of aggressive mantle cell lymphoma. CD70
18 34267181 10.1038/s41408-021-00521-4 2021 Lack of intrafollicular memory CD4 + T cells is predictive of early clinical failure in newly diagnosed follicular lymphoma. CD70
19 34313014 10.1002/cac2.12201 2021 CD70-targeting CAR-T cells have potential activity against CD19-negative B-cell Lymphoma. CD70
20 34638238 10.3390/cancers13194752 2021 Epstein-Barr Virus in Inborn Immunodeficiency-More Than Infection. CD70
21 31738823 10.1182/blood.2019002699 2020 Distinct molecular profile of IRF4-rearranged large B-cell lymphoma. CD70
22 32298986 10.1016/j.tranon.2020.100770 2020 Efficacy of B7-H3-Redirected BiTE and CAR-T Immunotherapies Against Extranodal Nasal Natural Killer/T Cell Lymphoma. CD70
23 32380537 10.1182/bloodadvances.2019001079 2020 Safety and activity of varlilumab, a novel and first-in-class agonist anti-CD27 antibody, for hematologic malignancies. CD70
24 32439996 10.1038/s41598-020-65463-6 2020 GSEA-assisted gene signatures valid for combinations of prognostic markers in PCNSL. CD70
25 32451662 10.1007/s10875-020-00790-x 2020 An Update on XMEN Disease. CD70
26 32603431 10.1182/blood.2020006738 2020 Extended clinical and immunological phenotype and transplant outcome in CD27 and CD70 deficiency. CD70
27 32620996 10.1007/s10875-020-00816-4 2020 Lymphoma Predisposing Gene in an Extended Family: CD70 Signaling Defect. CD70
28 32727777 10.21873/anticanres.14452 2020 Novel Anti-CD70 Antibody Drug Conjugate for the Treatment of Adult T-Cell Leukemia (ATL). CD70
29 33162537 10.11406/rinketsu.61.1365 2020 [Lymphoproliferative disorders and inborn errors of immunity]. CD70
30 29800648 10.1016/j.jaci.2018.04.030 2019 Activating PIK3CD mutations impair human cytotoxic lymphocyte differentiation and function and EBV immunity. CD70
31 30132271 10.1007/s10637-018-0655-0 2019 A phase 1 trial of SGN-CD70A in patients with CD70-positive diffuse large B cell lymphoma and mantle cell lymphoma. CD70
32 30784598 10.1016/j.celrep.2019.01.085 2019 Mass Cytometry Analysis Reveals that Specific Intratumoral CD4<sup>+</sup> T Cell Subsets Correlate with Patient Survival in Follicular Lymphoma. CD70
33 31014360 10.1186/s13045-019-0726-5 2019 Targeting CLL-1 for acute myeloid leukemia therapy. CD70
34 31292525 10.1038/s41598-019-46473-5 2019 Differential expression of individual transcript variants of PD-1 and PD-L2 genes on Th-1/Th-2 status is guaranteed for prognosis prediction in PCNSL. CD70
35 31402499 10.1111/imr.12791 2019 Signaling pathways involved in the T-cell-mediated immunity against Epstein-Barr virus: Lessons from genetic diseases. CD70
36 31597848 10.11406/rinketsu.60.1229 2019 [The immune microenvironment in malignant lymphoma]. CD70
37 31652572 10.3390/cancers11101611 2019 Screening a Broad Range of Solid and Haematological Tumour Types for CD70 Expression Using a Uniform IHC Methodology as Potential Patient Stratification Method. CD70
38 31678777 10.1016/j.scr.2019.101612 2019 Generation of a human induced pluripotent stem cell line (PHAi003) from a primary immunodeficient patient with CD70 mutation. CD70
39 31867275 10.3389/fonc.2019.01350 2019 CD19 and CD70 Dual-Target Chimeric Antigen Receptor T-Cell Therapy for the Treatment of Relapsed and Refractory Primary Central Nervous System Diffuse Large B-Cell Lymphoma. CD70
40 29282224 10.15252/emmm.201708292 2018 Loss of RASGRP1 in humans impairs T-cell expansion leading to Epstein-Barr virus susceptibility. CD70
41 29311309 10.1073/pnas.1713607115 2018 Signaling by the Epstein-Barr virus LMP1 protein induces potent cytotoxic CD4<sup>+</sup> and CD8<sup>+</sup> T cell responses. CD70
42 29564225 10.3389/fonc.2018.00054 2018 Mechanisms of Immune Evasion and Immune Modulation by Lymphoma Cells. CD70
43 28011863 10.1084/jem.20160784 2017 Inherited CD70 deficiency in humans reveals a critical role for the CD70-CD27 pathway in immunity to Epstein-Barr virus infection. CD70
44 28011864 10.1084/jem.20160849 2017 Combined immunodeficiency and Epstein-Barr virus-induced B cell malignancy in humans with inherited CD70 deficiency. CD70
45 28495792 10.1182/blood-2016-12-756585 2017 CD70 reverse signaling enhances NK cell function and immunosurveillance in CD27-expressing B-cell malignancies. CD70
46 28729334 10.1182/blood-2017-06-786244 2017 CD70 turns on NK cells to attack lymphoma. CD70
47 28783700 10.1126/sciimmunol.aan0291 2017 It's all in the family. CD70
48 29158380 10.1073/pnas.1710877114 2017 Anti-SIRPα antibody immunotherapy enhances neutrophil and macrophage antitumor activity. CD70
49 26077361 10.3109/10428194.2015.1063140 2016 Clinical significance of CD70 expression on T cells in human T-lymphotropic virus type-1 carriers and adult T cell leukemia/ lymphoma patients. CD70
50 26576779 10.1007/s00280-015-2909-2 2016 First-in-human multicenter phase I study of BMS-936561 (MDX-1203), an antibody-drug conjugate targeting CD70. CD70
51 26914723 10.1517/14728222.2016.1158812 2016 Therapeutic targeting of CD70 and CD27. CD70
52 27053012 10.3892/mmr.2016.5089 2016 Digital gene expression profiling analysis of childhood acute lymphoblastic leukemia. CD70
53 27708227 10.18632/oncotarget.12357 2016 T-cell responses against CD19+ pediatric acute lymphoblastic leukemia mediated by bispecific T-cell engager (BiTE) are regulated contrarily by PD-L1 and CD80/CD86 on leukemic blasts. CD70
54 25582824 10.1038/mt.2015.4 2015 Enhancing antitumor efficacy of chimeric antigen receptor T cells through constitutive CD40L expression. CD70
55 24569779 10.1038/leu.2014.84 2014 TGF-β upregulates CD70 expression and induces exhaustion of effector memory T cells in B-cell non-Hodgkin's lymphoma. CD70
56 25062112 10.1055/s-0034-1374640 2014 Significantly increased CD70 up regulation on TEL-AML positive B cell precursor acute lymphoblastic leukemia cells following CD40 stimulation. CD70
57 25142258 10.1007/s10637-014-0151-0 2014 Phase I dose-escalation study of SGN-75 in patients with CD70-positive relapsed/refractory non-Hodgkin lymphoma or metastatic renal cell carcinoma. CD70
58 25171927 10.1182/blood-2013-12-546309 2014 Exome sequencing reveals novel mutation targets in diffuse large B-cell lymphomas derived from Chinese patients. CD70
59 22801960 10.3324/haematol.2012.068791 2013 Combined immunodeficiency with life-threatening EBV-associated lymphoproliferative disorder in patients lacking functional CD27. CD70
60 23206232 10.1111/bjh.12136 2013 Expression of CD70 in nasal natural killer/T cell lymphoma cell lines and patients; its role for cell proliferation through binding to soluble CD27. CD70
61 23716461 10.1002/gcc.22072 2013 The costimulatory molecule CD70 is regulated by distinct molecular mechanisms and is associated with overall survival in diffuse large B-cell lymphoma. CD70
62 23808985 10.1021/bc400217g 2013 A potent anti-CD70 antibody-drug conjugate combining a dimeric pyrrolobenzodiazepine drug with site-specific conjugation technology. CD70
63 21994111 10.1002/pbc.23352 2012 Aggressive peripheral CD70-positive T-cell lymphoma associated with severe chronic active EBV infection. CD70
64 22213068 10.1002/ijc.27416 2012 Recurrent deletions of the TNFSF7 and TNFSF9 genes in 19p13.3 in diffuse large B-cell and Burkitt lymphomas. CD70
65 21182090 10.1002/eji.201040905 2011 CD70-CD27 interactions provide survival and proliferative signals that regulate T cell receptor-driven activation of human γδ peripheral blood lymphocytes. CD70
66 21304103 10.1182/blood-2010-04-278218 2011 T cells redirected against CD70 for the immunotherapy of CD70-positive malignancies. CD70
67 21606482 10.1182/blood-2010-09-307330 2011 RAC2, AEP, and ICAM1 expression are associated with CNS disease in a mouse model of pre-B childhood acute lymphoblastic leukemia. CD70
68 22065141 2011 Therapeutic monoclonal antibodies for multiple myeloma: an update and future perspectives. CD70
69 19806404 10.1007/s11307-009-0264-6 2010 Two-step in vivo tumor targeting by biotin-conjugated antibodies and superparamagnetic nanoparticles assessed by magnetic resonance imaging at 1.5 T. CD70
70 20048186 10.1200/JCO.2009.22.8254 2010 Investigational immunotherapeutics for B-cell malignancies. CD70
71 19109206 10.4049/jimmunol.182.1.718 2009 The CD70/CD27 pathway is critical for stimulation of an effective cytotoxic T cell response against B cell precursor acute lymphoblastic leukemia. CD70
72 19346216 10.1074/mcp.M800515-MCP200 2009 Protein profiling of plasma membranes defines aberrant signaling pathways in mantle cell lymphoma. CD70
73 19362984 10.3816/CLM.2009.n.024 2009 Novel antibody-based therapeutic agents targeting CD70: a potential approach for treating Waldenström's macroglobulinemia. CD70
74 19386499 10.1016/j.bmcl.2009.03.145 2009 Novel immunoconjugates comprised of streptonigrin and 17-amino-geldanamycin attached via a dipeptide-p-aminobenzyl-amine linker system. CD70
75 19452318 10.1080/10428190902803677 2009 Enhanced formation and survival of CD4+ CD25hi Foxp3+ T-cells in chronic lymphocytic leukemia. CD70
76 19509224 10.1158/0008-5472.CAN-09-0266 2009 Malignant B cells skew the balance of regulatory T cells and TH17 cells in B-cell non-Hodgkin's lymphoma. CD70
77 19573080 10.1111/j.1365-2141.2009.07790.x 2009 Common genetic variants in candidate genes and risk of familial lymphoid malignancies. CD70
78 19773279 10.1136/oem.2008.044024 2009 Association between genetic variants in VEGF, ERCC3 and occupational benzene haematotoxicity. CD70
79 18256142 10.1128/JVI.02013-07 2008 Highly enhanced expression of CD70 on human T-lymphotropic virus type 1-carrying T-cell lines and adult T-cell leukemia cells. CD70
80 19047103 10.1158/1078-0432.CCR-08-0493 2008 Preclinical characterization of SGN-70, a humanized antibody directed against CD70. CD70
81 17038522 10.1182/blood-2006-07-034017 2007 Engineered anti-CD70 antibody with multiple effector functions exhibits in vitro and in vivo antitumor activities. CD70
82 17311995 10.1182/blood-2006-11-057216 2007 Eradication of lymphoma by CD8 T cells following anti-CD40 monoclonal antibody therapy is critically dependent on CD27 costimulation. CD70
83 17615291 10.1182/blood-2007-03-082578 2007 CD70+ non-Hodgkin lymphoma B cells induce Foxp3 expression and regulatory function in intratumoral CD4+CD25 T cells. CD70
84 17877845 10.3816/clm.2007.s.023 2007 Novel agents in the treatment of Waldenström's macroglobulinemia. CD70
85 16275070 10.1016/j.bmcl.2005.09.081 2006 Dipeptide-based highly potent doxorubicin antibody conjugates. CD70
86 16704224 10.1021/bc0600214 2006 Development and properties of beta-glucuronide linkers for monoclonal antibody-drug conjugates. CD70
87 18528464 2006 Theodore E. Woodward Award: development of novel, EBV-targeted therapies for EBV-positive tumors. CD70
88 16034459 10.1038/sj.gt.3302577 2005 Herpes simplex virus type-1 amplicon vectors for vaccine generation in acute lymphoblastic leukemia. CD70
89 16272354 10.4049/jimmunol.175.10.6940 2005 Proliferation response of leukemic cells to CD70 ligation oscillates with recurrent remission and relapse in a low-grade lymphoma. CD70
90 16338493 10.1016/j.exphem.2005.10.005 2005 Expression of CD27-CD70 on early B cell progenitors in the bone marrow: implication for diagnosis and therapy of childhood ALL. CD70
91 16373719 10.1158/1535-7163.MCT-05-0253 2005 Anti-CD70 antibodies: a potential treatment for EBV+ CD70-expressing lymphomas. CD70
92 15359114 10.1023/B:JOCI.0000040926.37275.3b 2004 Resistance to cytotoxic chemotherapy is induced by NK cells in non-Hodgkin's Lymphoma Cells. CD70
93 11743585 10.1038/ni746 2002 Induction of tumor-specific T cell memory by NK cell-mediated tumor rejection. CD70
94 12421908 10.4049/jimmunol.169.10.5377 2002 Cutting edge: tumor rejection mediated by NKG2D receptor-ligand interaction is dependent upon perforin. CD70
95 12472567 10.1046/j.1365-2141.2002.03931.x 2002 Investigatory and analytical approaches to differential gene expression profiling in mantle cell lymphoma. CD70
96 11333903 10.1128/JVI.75.11.5215-5221.2001 2001 Enhancement of adenovirus vector entry into CD70-positive B-cell Lines by using a bispecific CD70-adenovirus fiber antibody. CD70
97 10800994 10.1097/00000478-200005000-00014 2000 CD70 expression in thymic carcinoma. CD70
98 10221513 10.3109/10428199909058433 1999 Modulation of costimulatory molecules on follicular lymphoma cells by TNF and CD40. CD70
99 10419648 10.1006/cyto.1998.0449 1999 CD27 signals through PKC in human B cell lymphomas. CD70
100 10444164 10.1046/j.1365-2141.1999.01474.x 1999 Involvement of the CD27-CD70 co-stimulatory pathway in allogeneic T-cell response to follicular lymphoma cells. CD70